“Biovac has secured a $15 million loan from the AfDB to construct Africa’s first end-to-end oral cholera vaccine facility and South Africa’s first locally produced inactivated polio vaccine plant. The project will boost Africa’s vaccine independence, scaling production to 500 million doses annually by 2028.”
South Africa’s biotechnology industry has taken another decisive step toward vaccine sovereignty. On July 27, 2026, the African Development Bank (AfDB) announced a $15 million loan to Biovac, the Biologicals and Vaccines Institute of South Africa, to fund the construction of a new multi-vaccine manufacturing facility in Cape Town. This investment represents a landmark moment in Africa’s fight against vaccine dependency, as the continent currently imports more than 99% of its vaccines.
Biovac’s Expansion Plans
The new facility will expand Biovac’s annual production capacity to 500 million doses by 2028. Initially, the plant will focus on producing oral cholera vaccines, followed by inactivated polio vaccines (IPV), pneumococcal conjugate vaccines (PCV), and meningitis vaccines (MenX). This diversification of vaccine output is critical for Africa, where infectious diseases remain a major public health challenge.
Strategic Partnerships
Biovac’s expansion is supported by technology-transfer agreements with global pharmaceutical leaders including Sanofi, Biological E Limited, EuBiologics, and Bharat Biotech. These collaborations will ensure that the facility meets international standards and accelerates Africa’s integration into global vaccine supply chains.
AfDB’s Vision for Health Sovereignty
According to AfDB Vice President Solomon Quaynor, the investment is about “building Africa’s health sovereignty, strengthening regional value chains, and creating industrial capabilities that will enable the continent to respond more effectively to future health emergencies.” This statement underscores the broader ambition: transforming Africa from a consumer of imported vaccines into a producer of critical health solutions.
Integration with Global Health Initiatives
The project will connect directly with the World Health Organization’s (WHO) Gavi African Vaccine Manufacturing Accelerator, a $1.2 billion mechanism designed to reward African manufacturers with milestone payments once they achieve WHO prequalification. This integration ensures that Biovac’s vaccines will not only serve South Africa but also reach broader African and global markets.
Economic and Social Impact
Beyond health benefits, the facility is expected to generate hundreds of skilled jobs in biotechnology, engineering, and regulatory compliance. It will also stimulate South Africa’s biotech ecosystem, encouraging innovation and investment in related fields such as biologics and diagnostics.
Challenges Ahead
Despite the optimism, challenges remain. Scaling production to 500 million doses requires robust infrastructure, skilled workforce retention, and streamlined regulatory approvals. South Africa must also address supply chain vulnerabilities, particularly in sourcing raw materials for vaccine production.
Regional Significance
For Africa, this facility represents a turning point. The COVID-19 pandemic exposed the continent’s vulnerability to global supply chain disruptions. By producing vaccines locally, South Africa positions itself as a continental hub for biotechnology, reducing reliance on imports and strengthening pandemic preparedness.
Conclusion
Biovac’s new facility, backed by AfDB’s $15 million loan, is more than a manufacturing plant—it is a symbol of Africa’s determination to achieve vaccine sovereignty. By 2028, Cape Town could become the epicenter of Africa’s vaccine independence, reshaping the continent’s healthcare landscape and ensuring that future generations are better protected against preventable diseases.
